Physician profile
William B Hooks
NPI 1225249253
$11,371.91
in general payments reported to CMS, 2019-2025
27 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $267 · 2021: $442 · 2022: $900 · 2023: $344 · 2024: $8,078 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,000 · Food and Beverage: $2,175 · Travel and Lodging: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,000.00 |
| Food and Beverage | $2,174.79 |
| Travel and Lodging | $1,110.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Distalmotion US | $7,237.67 | 2024 | Dexter L6 Robot |
| Ethicon US, LLC | $772.63 | 2019-2025 | Vistaseal, Ethicon, Harmonic |
| Intuitive Surgical, INC. | $639.58 | 2019-2025 | |
| Tela Bio, INC. | $399.37 | 2021-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Smith+Nephew, INC. | $385.08 | 2019-2025 | Stravix, Grafix Pl, Oasis |
| Medtronic, INC. | $354.59 | 2023-2025 | Progrip, Gi Genius, Transorb |
| Endogastric Solutions, INC | $212.95 | 2022 | |
| Davol INC. | $185.94 | 2022-2025 | Phasix Mesh |
| Merck Sharp & Dohme LLC | $173.77 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Integra Lifesciences Corporation | $154.70 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Rti Surgical, INC | $147.44 | 2025 | |
| Teleflex LLC | $115.76 | 2021 | |
| Kerecis Limited | $93.26 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Conmed Corporation | $90.70 | 2021 | |
| Acell, INC. | $72.32 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanara Medtech INC. | $39.54 | 2024-2025 | Celleraterx, Celleraterx |
| Kci USA, INC. | $39.43 | 2019 | |
| Intra-Sana Laboratories | $35.04 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Abbvie INC. | $33.86 | 2024 | |
| Solventum Corporation | $33.00 | 2024 | Activ.A.C. |
| Covidien LP | $28.88 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $27.51 | 2025 | |
| Heron Therapeutics, INC. | $23.19 | 2025 | Aponvie |
| Musculoskeletal Transplant Foundation INC. | $22.41 | 2022 | |
| Allergan, INC. | $20.59 | 2020 | |
| Convatec INC. | $18.40 | 2020 | |
| Aroa Biosurgery Incorporated | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.